Download Files:
Products Details
Product Description
– Anagrelide, an inhibitor of phosphodiesterase type III (PDEIII) (IC50=36 nM), inhibits platelet production. Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide plays in the antithrombopoietic action. The platelet-lowering agent[1].
Web ID
– HY-B0523
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C10H7Cl2N3O
References
– [1]Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146(3):324-32.|[2]Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20(6):1117-22.|[3]Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25(5):1676-1687.
CAS Number
– 68475-42-3
Molecular Weight
– 256.09
SMILES
– O=C1NC2=NC3=C(C(Cl)=C(Cl)C=C3)CN2C1
Clinical Information
– Launched
Research Area
– Cancer; Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Phosphodiesterase (PDE)
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
